Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

• Published in: Leukemia & lymphoma 2018-01, Vol.59 (1), p.85-96
• Main Authors: Hazar, Volkan, Kesik, Vural, Karasu, Gülsün Tezcan, Öztürk, Gülyüz, Küpesiz, Alphan, Kılıç, Suar Çakı, Ataş, Erman, Uygun, Vedat, Eker, Nurşah, Erbey, Fatih, Bengoa, Şebnem Yılmaz, Emir, Suna, Anak, Sema, Öniz, Haldun, Daloğlu, Hayriye, Aksoylar, Serap, Koçak, Ülker, Karakükçü, Musa, Elli, Murat, Kurucu, Nilgün, Yeşilipek, Akif
• Format: Article
• Language: English
• Subjects: Adolescent; Child; Child, Preschool; children and adolescents; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin - epidemiology; Lymphoma, Non-Hodgkin - mortality; Lymphoma, Non-Hodgkin - pathology; Lymphoma, Non-Hodgkin - therapy; Male; Neoplasm Staging; Prognosis; Recurrence; Registries; Relapsed or refractory non-Hodgkin lymphoma; Retrospective Studies; Risk Factors; Transplantation, Homologous; Treatment Outcome; Turkey - epidemiology
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2017.1330472

We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p